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Abstract
Background: CSF-1 or IL-34 stimulation of CSF1R promotes macrophage differentiation, activation and
osteoclastogenesis, and pharmacological inhibition of CSF1R is beneficial in animal models of arthritis. The objective of
this study was to determine the relative contributions of CSF-1 and IL-34 signaling to CSF1R in RA.
Methods: CSF-1 and IL-34 were detected by immunohistochemical and digital image analysis in synovial tissue from
15 biological-naïve rheumatoid arthritis (RA) , 15 psoriatic arthritis (PsA) and 7 osteoarthritis (OA) patients . Gene
expression in CSF-1- and IL-34-differentiated human macrophages was assessed by FACS analysis and quantitative PCR.
RA synovial explants were incubated with CSF-1, IL-34, control antibody (Ab), or neutralizing/blocking Abs targeting
CSF-1, IL-34, or CSF1R. The effect of a CSF1R-blocking Ab was examined in murine collagen-induced arthritis (CIA).
Results: CSF-1 (also known as M-CSF) and IL-34 expression was similar in RA and PsA synovial tissue, but lower in
controls (P < 0.05). CSF-1 expression was observed in the synovial sublining, and IL-34 in the sublining and the intimal
lining layer. CSF-1 and IL-34 differentially regulated the expression of 17 of 336 inflammation-associated genes in
macrophages, including chemokines, extra-cellular matrix components, and matrix metalloproteinases. Exogenous
CSF-1 or IL-34, or their independent neutralization, had no effect on RA synovial explant IL-6 production. Anti-CSF1R Ab
significantly reduced IL-6 and other inflammatory mediator production in RA synovial explants, and paw swelling and
joint destruction in CIA.
Conclusions: Simultaneous inhibition of CSF1R interactions with both CSF-1 and IL-34 suppresses inflammatory
activation of RA synovial tissue and pathology in CIA, suggesting a novel therapeutic strategy for RA.
Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease that affects the peripheral joints, leading to joint de-
formity and destruction [1]. Synovial macrophages,
through their ability to release inflammatory cytokines,
matrix metalloproteinases (MMPs), chemokines, reactive
oxygen and nitrogen intermediates, and prostanoids,
play a central role in the pathological process of RA [2].
Importantly, macrophage numbers and cytokine prod-
ucts are associated with disease activity and disease pro-
gression in RA, and decreases in synovial sublining
CD68+ macrophages represent a sensitive biomarker of
effective treatment [2]. Therefore, strategies specifically
designed to target the activation, survival, or pro-
inflammatory differentiation of macrophages in synovial
tissue may be of therapeutic benefit in RA [2, 3].
Colony-stimulating factors (CSF) and functionally re-
lated cytokines regulate myeloid lineage cell development,
proliferation, survival, mobilization, differentiation, and
activation in both health and disease [4]. Granulocyte-
macrophage CSF (GM-CSF) plays an important role in
* Correspondence: k.a.reedquist@umcutrecht.nl
1Department of Experimental Immunology, Academic Medical Center,
University of Amsterdam, Amsterdam, The Netherlands
2Department of Clinical Immunology and Rheumatology, Academic Medical
Center, University of Amsterdam, Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2016 Garcia et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Garcia et al. Arthritis Research & Therapy  (2016) 18:75 
DOI 10.1186/s13075-016-0973-6
promoting the differentiation of granulocytes and macro-
phages from hematopoietic precursors [4]. During inflam-
mation this property of GM-CSF may be important for
the sustained recruitment of immature monocytes to af-
fected tissues [5–7]. GM-CSF may also directly contribute
to inflammation by polarizing macrophages into a pro-
inflammatory phenotype, and participating in cytokine
networks with other pro-inflammatory cytokines such as
TNF and interleukin (IL)-1β [8, 9]. Administration of ex-
ogenous GM-CSF has been demonstrated to exacerbate
collagen-induced arthritis (CIA) in mice, while mice defi-
cient in GM-CSF expression are protected against disease
in this model of arthritis [6, 10–13]. Additionally, neutral-
izing antibodies (Abs) against GM-CSF display both
prophylactic and therapeutic efficacy in experimental arth-
ritis [6, 14]. The direct relevance of these findings to RA is
exemplified in recent clinical trials in which a blocking Ab
directed at the alpha chain of the GM-CSF receptor has
demonstrated safety and efficacy [15, 16].
Colony-stimulating factor-1 (CSF-1), through binding to
the tyrosine kinase receptor CSF1R (also known as c-fms),
also promotes the survival, proliferation and differenti-
ation of myeloid cells, including monocytes, macrophages
and osteoclasts [4, 17]. CSF-1 plays a distinctly different
role from GM-CSF in myelopoiesis, acting as a survival
and differentiation factor for mature circulating mono-
cytes (Ly6Clo in mice, CD16+ in humans) and resident tis-
sue macrophages [6, 17, 18]. In RA, CSF-1 is produced
mainly by synovial endothelial cells, but in vitro data indi-
cate that synovial fibroblasts and chondrocytes stimulated
with TNF or IL-1β also produce CSF-1 [19–21]. Animal
models have shown that exogenous administration of
CSF-1, like GM-CSF, exacerbates the incidence and sever-
ity of CIA, while anti-CSF-1 Ab, genetic deletion of CSF-
1, and pharmacological inhibitors of CSF1R reduce the se-
verity of experimental arthritis [11, 12, 22, 23]. CSF-1 also
has an essential function in joint destruction, as CSF-1 is
required for osteoclastogenesis and TNF-induced osteoly-
sis [24, 25].
IL-34 was recently discovered as a novel ligand of
CSF1R through its ability to support monocyte viability
[26]. CSF-1 and IL-34 share structural, but not sequence
homology, and have largely overlapping effects on CSF1R
downstream signaling, regulation of monocyte survival,
macrophage polarization, and osteoclastogenesis [27–32].
However, during murine development, IL-34 plays a non-
redundant role in the generation of Langerhans cells and
microglia [33, 34]. Recent studies have reported that IL-34
levels are elevated in the serum, synovial fluid, and syn-
ovial tissue of RA patients, and like CSF-1, IL-34 is in-
duced by TNF and IL-1β in RA fibroblast-like
synoviocytes (FLS) [35–38]. The goal of this study was to
determine the relative contributions of CSF-1 and IL-34
to CSF1R-dependent inflammation in RA.
Methods
Patients and tissue donors
Synovial biopsies were obtained by needle arthroscopy
as previously described from clinically active joints in
patients with RA (n = 15), psoriatic arthritis (PsA) (n =
15), or osteoarthritis (OA) (n=7), as previously described
[39]. RA and PsA patients fulfilled the 1987 American
College of Rheumatology criteria for RA and the classifi-
cation of psoriatic arthritis study (CASPAR) criteria, re-
spectively [40, 41]. Patient clinical characteristics are
detailed in Additional file 1: Tables S1 and S2. All pa-
tients gave their written informed consent prior to study
inclusion, and this study was approved by the Medical
Ethics Committee of the Academic Medical Center,
University of Amsterdam, and in accordance with the
Declaration of Helsinki.
Immunohistochemical and digital imaging analysis
Serial sections from six different TissueTek-embedded
biopsy samples per patient were cut with a cryostat
(5 μm), fixed with acetone, and endogenous peroxidase
activity blocked with 0.3 % hydrogen peroxide in 0.1 %
sodium azide/phosphate-buffered saline. Sections were
stained overnight at 4°C with Abs against CSF-1 (R&D),
IL-34 (M4, provided by Five Prime Therapeutics Inc.) and
CD68 (Dako). Equivalent concentrations of irrelevant
mouse monoclonal Abs were used as negative controls.
Sections were then washed and incubated with goat anti-
mouse-horseradish peroxidase (HRP) (Dako), except in
the case of anti-IL-34 Ab, which was followed by incuba-
tion with biotinylated tyramide and streptavidin-HRP.
Sections were developed with amino-ethylcarbazole
(AEC, Vector Laboratories), counterstained with Gill’s
hematoxylin (Klinipath), and mounted in Kaiser’s glycerol
gelatine (Merck). Stained sections were analyzed by
computer-assisted image analysis using the Qwin analysis
system (Leica) as previously described in detail [42].
Values of integrated optical densities (IOD)/mm2 were ob-
tained and corrected for the total number of nuclei/mm2.
Data were presented as the number of positive cells/mm2
for quantitative analysis of cell-type-specific markers.
Monocyte purification and macrophage differentiation
Human mononuclear cells were isolated from volunteer
donor blood buffy coats (Sanquin), peripheral blood
from healthy controls and RA patients, and from syn-
ovial fluid of RA patients by gradient centrifugation with
Lymphoprep (Axis-Shield PoPAS) and monocytes were
further isolated by Percoll gradient separation (GE
Healthcare). Monocytes were differentiated into macro-
phages in IMDM/10 % fetal calf serum (FCS) supple-
mented with 100 μg/ml gentamycin (Invitrogen), in the
presence of human GM-CSF (5 ng/ml, R&D Systems),
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CSF-1 (25 ng/ml, R&D Systems), or IL-34 (25 ng/ml,
provided by Five Prime Therapeutics Inc.) for 7 days.
Flow cytometry
Macrophage purity and differentiation were assessed by
flow cytometry (FACS Canto Flow Cytometer, BD
Biosciences). Fluorochrome-labeled monoclonal Abs
against CD14 (eBiosciences), CD206 and CD163 (both
from BD Pharmingen), CD64 (Biolegend), and equiva-
lent concentrations of isotype control Abs were used.
Before staining, Fc receptors were blocked with 10 % hu-
man serum (Lonza). Data were analyzed with FlowJo
Flow Cytometry Analysis software (Tree Star). Values
were expressed as the ratio of the geometric mean fluor-
escence intensity (geomean) of the marker of interest
over that of the isotype control.
Macrophage cell death and viability
Macrophage cell death was assessed by Annexin V-
propidium iodide (PI) staining. GM-CSF-, IL-34-, and
CSF-1-differentiated macrophages in peripheral blood
from healthy donors and in peripheral blood and syn-
ovial fluid from RA patients were stained with
Annexin V (1:100 dilution, iQ products) and PI (1:100
dilution, iQ products) and measured using a FACS
Canto Flow Cytometer. Data were analyzed with
FlowJo Flow Cytometry Analysis software. Values were
expressed as the percentage of Annexin V-PI double-
positive cells. Macrophage viability was assessed by
the calcein assay. Monocytes from the buffy coat were
differentiated into macrophages with medium alone,
CSF-1 or IL-34 and cell proliferation was analyzed at
days 1, 3 and 7 by staining with Calcein-AM (1 μM,
BD Bioscience) and analysis using a multi-label reader
Victor3™ (PerkinElmer Inc.). Data were expressed as
signal in arbitrary units.
Real-time (RT) PCR and quantitative (q)PCR arrays
RNA from frozen synovial biopsies or from GM-CSF-,
IL-34- and CSF-1-differentiated macrophages was iso-
lated using the RNeasy Kit and RNase-Free DNase Set
(Qiagen). Patient clinical characteristics are detailed in
Additional file 1: Table S3. Total RNA was reverse-
transcribed using SuperScript™ II RT (Invitrogen). Dupli-
cate PCR reactions were performed using SYBR green
(Applied Biosystems) with an ABI Prism® 7000 sequence
detection system (Applied Biosystems). Complementary
DNA (cDNA) was amplified using specific primers
(Invitrogen) (see Additional file 1: Table S4). Relative levels
of gene expression were normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping gene.
Messenger RNA (mRNA) expression was presented as 2-
ΔCt or relative quantity (RQ, 2-ΔΔCt). Alternatively, total
RNA was subjected to cDNA synthesis using an RT2 First
Strand Kit (Qiagen) and mRNA expression of 336
inflammation-related genes was analyzed by RT-qPCR
using low density qPCR arrays (Human Angiogenic Growth
Factors & Angiogenesis Inhibitors, Human Extracellular
Matrix & Adhesion Molecules and Human TGFß/BMP
Signaling Pathway PCR Arrays, Qiagen). Relative levels of
gene expression were normalized to five housekeeping
genes and RQ values determined as above.
Antibodies
Anti-human CSF-1 Ab, clone 26730, a neutralizing
mouse IgG2a monoclonal Ab, was purchased from R&D
Systems, Minneapolis, MN, USA. Anti-human IL-34
Abs M2 and M4 were provided by Five Prime Therapeu-
tics. M2 and M4 monoclonal Abs were prepared by
immunization of Balb/c mice with purified human IL-34
produced at Five Prime Therapeutics, followed by stand-
ard hybridoma procedures and protein A purification.
All animal experiments in this study were performed in
compliance with appropriate protocols approved by the
Institutional Animal Care and Use Committee at Five
Prime Therapeutics and Bolder Biopath (Boulder, CO,
USA). The M2 Ab was determined to be a blocking Ab,
and the M4 Ab was determined to be a non-blocking Ab
by testing hybridoma supernatant for the ability to block bi-
otinylated IL-34-binding to human CSF1R-Fc in an ELISA
format, and by testing the ability of purified Ab to
neutralize IL-34-mediated survival of primary human
monocytes. Anti-human CSF1R Ab huAB1, a humanized
IgG4, monoclonal Ab, was provided by Five Prime Thera-
peutics. huAB1 blocks the binding of both CSF-1 and IL-34
to the human CSF1R, thereby inhibiting CSF1R-mediated
signaling pathways (see Additional file 2: Figure S1a). Anti-
mouse CSF1R Ab muAB5, was provided by Five Prime
Therapeutics and is a chimeric IgG1, monoclonal Ab con-
sisting of rat V regions and murine C regions. muAB5
blocks the binding of both mouse CSF-1 and mouse IL-34
to the mouse CSF1R, thereby inhibiting CSFR-mediated re-
sponses (see Additional file 2: Figure S1b). Anti-CSF1R
treatment in mice has been reported to selectively reduce
peripheral Ly6Clo monocytes while having no effect on
Ly6Chi monocyte numbers [6, 18]. To assess the impact of
anti-mouse CSF1R muAB5 on peripheral monocytes, we
treated mice with 20 mg/kg of muAB5 or saline and 7 days
later quantified monocyte populations in the blood. Anti-
CSF1R muAB5 selectively reduced the number of
Ly6Clo monocytes while having little to no effect on
Ly6Chi monocytes (see Additional file 2: Figure S2).
Synovial biopsy explant assays
Intact synovial biopsies (5 mm3) were obtained from the
knees of patients with RA and were cultured, three biop-
sies per condition, for 24 h in complete DMEM supple-
mented with 10 % FCS and stimulated for 24 h with
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increasing concentrations of human IL-34 or CSF-1. Alter-
natively, explants were cultured for 96 h with anti-human
CSF-1 (5 μg/ml), anti-IL-34 (5 μg/ml, M2), increasing con-
centrations of anti-human CSF1R Ab (huAB1), or their re-
spective human isotype controls (Eureka Therapeutics).
Cell-free tissue culture supernatants were harvested for
cytokine analysis. Patient clinical characteristics are detailed
in Additional file 1: Table S4.
Measurement of cytokine production
Cell-free supernatants from synovial biopsies were ana-
lyzed by ELISA for IL-6 (PelKine Compact™ ELISA kits,
Sanquin Reagents). CCL2, CCL-7, ENA-78, SDF-1, MIG,
GCP-2, TAC, NAP-2, IP-10, IL-1β, TNF-α, CXCL-8,
MMP-2, MMP-7, and MMP-9 were measured using hu-
man single-plex assays (Bio-Rad) and read on a Bio-Plex
200 system (Bio-Rad).
Effects of anti-CSF1R Ab on murine myeloid homeostasis
CB17 SCID mice (3–5/group) were injected intravenously
with 20 mg/kg of muAB5 or saline. Seven days later 50 μl
of whole blood was harvested into FACS buffer containing
ethylenediaminetetraacetic acid (EDTA) (MACs Rinsing
Buffer with BSA; Miltenyi Biotech) to prevent clotting.
Red blood cells were lysed by hypotonic lysis (0.16M
NH4Cl, 0.01M KCO3 and 0.1mM EDTA). Samples were
washed and Fc receptors blocked by staining with 5 μg/ml
anti-CD16/32 Ab (Clone: 93, eBioscience). Cells were
washed and stained with the following Abs: anti-mF4/80-
FITC (Clone: BM/8; Biolegend), anti-mCD11b-PE (Clone:
M1/70; BD Biosciences), anti-mLy6C-PerCP (Clone:
HK1.4; Biolegend) and anti-mLy6G-Alexa700 (Clone:
1A8; Biolegend). To facilitate identification of dead cells the
samples were stained with Aqua Live/Dead© (Invitrogen)
according to the manufacturer’s recommendations. Cells
were washed, pellets were resuspended in 50 μl of FACs
buffer, and 50 μl of CountBright™ Absolute Counting Beads
(Invitrogen) were added to each sample. Samples were
thoroughly mixed and run on a BD LSRII flow cyt-
ometer (BD Biosciences). Data files were analyzed using
Flow Jo software v.7.6.4 (Treestar Inc.)
Induction and assessment of CIA and histopathological
analysis
The mouse CIA models were established at Bolder Bio-
path. Male DBA/1 mice (12/group) were injected intra-
dermally at the base of the tail with 150 μl of Freund’s
Complete Adjuvant containing bovine type II collagen
(2 mg/ml) on day 0 and day 21. For prophylactic treat-
ment mice were dosed starting on day 0 with vehicle,
Enbrel at 10 mg/kg, or muAB5 at 30 mg/kg. Treatment
continued three times weekly through day 32. Clinical
sores on a scale of 0–5 were determined for each of the
paws on study days 18–35. The study was terminated on
day 35 and blood was collected. Hind paws and knees were
collected at termination and processed for histological
analysis, as detailed in Additional file 3: Supplementary
methods. For therapeutic treatment, mice were immunized
as outlined above and randomized into treatment groups
once swelling was obviously established in at least one paw.
Group mean scores were 0.5–1.0 (out of a possible max-
imal score of 5.0) at the time of enrollment. Treatment with
vehicle, Enbrel at 10 mg/kg, or muAB5 at 30 mg/kg was
initiated after enrollment and continued three times weekly
through day 20 of arthritis with mice terminated on day 23
of arthritis. Drug exposure as measured by the terminal
plasma concentration was below the limit of detection in 3
out of 12 animals in the muAB5-treated group. These sam-
ples tested positive for anti-drug antibodies (data not
shown), which likely contributed to the poor exposure.
Based on these findings, these 3 animals with undetectable
drug levels were excluded from any of the study analysis
and interpretation: 7 the 12 animals in the Enbrel-treated
group also had no detectable drug at termination and were
excluded from the analysis.
TRAP5b analysis
Mouse serum band 5 tartrate-resistant acid phosphatase
isoform b (TRAP5b) was measured in mouse EDTA
plasma using a commercial ELISA kit (MouseTRAP™
Assay, Immunodiagnostic Systems, Inc.) as per the man-
ufacturer’s instructions, including a 1:4 dilution of all
samples, using plasma instead of serum. Each sample
was tested in singlet. The standard curve absorbance vs.
concentration data were fit to a four-parameter logistic
for calculation of the test results. Results are reported in
units/liter (U/L).
Statistical analyses
Statistical analysis was performed using Windows
GraphPad Prism 5 (GraphPad Software, Inc.). Potential
differences between experimental groups were analyzed
by the non-parametric Mann-Whitney U test, Kruskal-
Wallis test, or Friedman paired test, as appropriate.
P values <0.05 were considered statistically significant.
Results
Synovial tissue expression of CSF-1, IL-34 and CSF1R
First, we investigated the expression of CSF-1, IL-34 and
CSF1R in the synovial tissue of patients with RA or PsA.
qPCR analysis did not identify any differences between
RA and PsA patients in mRNA expression of IL-34,
CSF-1, or their receptors (Fig. 1a). Immunohistochemi-
cal analysis of synovial tissue independently confirmed
that IL-34 (Fig. 1b) and CSF-1 (Fig. 1c) are expressed in
synovial tissue in RA, PsA and OA. While IL-34 is
expressed in the synovial sublining and the intimal lining
layer, CSF-1 expression was limited primarily to the
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areas surrounding the blood vessels. On digital quantifi-
cation of staining for each cytokine, IL-34 and CSF-1
protein expression was similar in synovial tissue in RA,
PsA, and OA (Fig. 1d). Together, these data demonstrate
that both IL-34 and CSF-1 are expressed at similar levels
in the synovium of patients with inflammatory and non-
inflammatory arthritis.
IL-34 and CSF-1 induce similar but distinct gene expression
patterns in human macrophages
Given that IL-34 and CSF-1 localized to distinct regions
of the synovium, and macrophages in RA and PsA syn-
ovial sublining and intimal lining layers display distinct
phenotypic characteristics [43], we examined the influ-
ence of these two cytokines in peripheral blood from
Fig. 1 Colony-stimulating factor-1 (CSF-1), IL-34 and CSF1 receptor (CSF1R) are expressed in synovial tissue from patients with rheumatoid
arthritis (RA) and psoriatic arthritis (PsA). a Quantification of relative IL-34, CSF-1 and CSF1R mRNA expression in synovial tissue from 6
patients with RA and 6 with PsA. Quantitative PCR data are shown as relative quantity (RQ), as described in “Methods”. Data are presented
as scatter plots, where each plot represents an individual value, bars represent the mean, and error bars indicate the standard error of the
mean (SEM). b, c Immunohistochemical analyses of RA, PsA and OA synovial tissue stained with control rabbit, anti-IL34 (b) and anti-CSF1
antibodies (c). d Quantitative analysis of IL-34 and CSF-1 staining in synovial tissue. Synovial sections from 15 patients with RA, 15 with
PsA and 7 patients with osteoarthritis (OA) were stained with antibodies against IL-34 and CSF-1 antibodies as above, and the integrated
optical density (IOD/mm2) corrected for cellularity was calculated by digital image analysis. Each plot represents an individual value, bars
represent the mean, and error bars indicate the SEM. *P < 0.05
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HD and patients with RA, and their influence on syn-
ovial fluid-derived monocyte differentiation, proliferation
and gene expression in RA. To test this, we differenti-
ated monocytes from mononuclear cells of buffy coats
in blood from HD, and peripheral blood and synovial
fluid from patients with RA with CSF-1 (CSF-1 Mφ), IL-
34 (IL-34 Mφ) or GM-CSF (GM-CSF Mφ). We first
analyzed the effect of IL-34 and CSF-1 on macrophage
proliferation and survival. We observed no differences in
cell survival in IL-34 Mφ and CSF-1 Mφ; however, there
was a trend towards greater cell death compared to
GM-CSF Mφ (Fig. 2a). We did not observe any differences
in cell viability between macrophages derived from mono-
nuclear cells in peripheral blood from HD or patients with
RA, nor between peripheral blood-derived and synovial
fluid-derived macrophages in patients with RA (Fig. 2a).
We also found that both CSF-1 and IL-34 promoted cell
survival similarly, and significantly enhanced viability
compared to macrophages differentiated in medium alone
(p < 0.05, see Additional file 2: Figure S3).
Next, we examined the expression of recently validated
polarization markers for human macrophages [43]. We
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Fig. 2 IL-34 and colony stimulating factor-1 (CSF-1) macrophages have similar phenotypic characteristics. a Fluorescence-activated cell sorting
(FACS) analysis of Annexin V-propidium iodide (PI) staining in macrophages differentiated for 7 days in granulocyte-macrophage colony-
stimulating factor (GM-CSF) (5 ng/ml), CSF-1 (25 ng/ml) or IL-34 (25 ng/ml) from peripheral blood and synovial fluid of healthy donors (HD) and
patients with rheumatoid arthritis (RA). Data are presented as percentage of double-positive cells and represent the mean ± standard error of the
mean (SEM) of 3–4 independent experiments. b, c FACS analysis of expression of macrophage surface markers CD14, CD163, CD206, and CD64 in
macrophages differentiated for 7 days in GM-CSF, CSF-1 or IL-34 derived from monocytes of buffy coat (b) or monocytes from peripheral blood
of HD or patients with RA (PB), or from synovial fluid from patients with RA (SF) (c). Data are presented as the geometric mean (geo mean) and
represent the mean ± SEM of 4–5 independent experiments per marker. *P < 0.05, **P < 0.01, and ***P < 0.001
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observed that the expression of CD14, CD163, CD206,
and CD64 was similar in IL-34 Mφ and CSF-1 Mφ, inde-
pendently if the macrophages were derived from periph-
eral blood from HD, or peripheral blood or synovial
fluid from patients with RA. In contrast, GM-CSF Mφ
had significantly lower expression of CD14 and CD163,
and elevated expression of CD206 and CD64 (Fig. 2b
and Fig. 2c).
Finally, we examined the mRNA expression of 336 genes
relevant to RA, involved in angiogenesis, extracellular
matrix remodeling and osteoclast formation. On unsuper-
vised clustergram analysis, GM-CSF Mφ derived from per-
ipheral blood from HD clustered distinctly compared to
those differentiated in IL-34 or CSF-1 (Fig. 3a), as ex-
pected. IL-34 and CSF-1 Mφ were closely related, with
more global differences between monocyte donors than
the cytokine used for differentiation. However, despite the
strong relationship in gene expression between macro-
phages differentiated in IL-34 and CSF-1, we identified a
number of genes that were significantly upregulated in
Fig. 3 Gene expression in differentiated macrophages. a mRNA expression profiles of 336 genes involved in angiogenesis, extracellular matrix
remodeling, and osteoclast formation in granulocyte-macrophage colony-stimulating factor (GM-CSF)-, colony-stimulating factor-1 (CSF-1)- or
IL-34-differentiated macrophages (Mφ) derived from monocytes of buffy coats (n = 3). Data are presented in an unsupervised clustergram. b
Analyses of mRNA expression levels of selected genes analyzed in a. Data are shown as relative quantity (RQ) in relation to GM-CSF Mφ, as described
in “Methods”
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CSF-1 Mφ, including CXCL5, TIE1, LMBP2, CDC25A,
ITGA6, LAMAC1, ECM1, and ITGB5 (Fig. 3a). In contrast,
the expression of CXCL12, SERPINF1, MMP2, ACVRA2,
ITGAL, CDH11, and TGFBR3 was significantly upregu-
lated in IL-34 Mφ (Fig. 3b and Additional file 1: Table S5).
We also examined whether IL-34 and CSF-1 Mφ dif-
ferentiated from synovial fluid (SF) monocytes in RA had
different expression patterns in genes related to extracellu-
lar matrix remodeling. We observed upregulation of
ADAMTS1, MMP3, MMP7, ITGA1, LAMA1, LAMA3,
LAMB3, and SSP1 in CSF-1 Mφ, while CDH11, MMP2,
and ITGB4 were upregulated in IL-34 Mφ (Fig. 4). To-
gether, these results suggest that while IL-34 and CSF-1
generate phenotypically similar macrophages, differential
localized production of IL-34 and CSF-1 in the synovium
could potentially give rise to macrophages with discrete
functional capacities.
CSF1R blockade reduces inflammatory mediator
production in RA synovial tissue
To extend our knowledge about the role of CSF1R sig-
naling in RA, we used blocking antibodies to CSF-1
(clone 26730), to IL-34 (M2), or to CSF1R (huMab1) to
investigate the differential effects of inhibiting responses
to each ligand independently versus inhibiting responses
to both ligands simultaneously through CSF1R blockade.
We first determined the effect of IL-34 and CSF-1
stimulation on cytokine production in RA synovial tis-
sue. Initial experiments demonstrated that addition of
either exogenous IL-34 or CSF-1 did not induce IL-6
production by RA synovial explants (Fig. 5a). To discard
the possibility that the receptor-type protein-tyrosine
phosphatase ζ (PTP-ζ), a recently discovered IL-34 re-
ceptor [44], could interfere in IL-6 production, we ana-
lyzed the mRNA expression in the synovial tissue of
patients with RA or PsA. We found that PTP-ζ was
expressed in the synovium in both diseases (see Additional
file 2: Figure S4), albeit at very low levels compared to
CSF1R. Moreover, neutralization of either IL-34 alone
(Fig. 5b) or of CSF-1 alone (Fig. 5c) did not influence IL-6
production by synovial explants. However, direct targeting
of CSF1R with huAb1, which blocks binding of both IL-34
and CSF-1, significantly reduced synovial explant IL-6
production in a dose-dependent manner, with maximum
inhibition already observed at an Ab concentration of 1
μg/ml (Fig. 5d). huAB1 also significantly reduced produc-
tion of the chemokines CXCL-8, GCP-2, MIG, IP-10,
CCL-2, CCL-7, and MMP-9 in RA synovial tissue (Fig. 5e),
Fig. 4 Gene expression in macrophages differentiated from synovial fluid monocytes in rheumatoid arthritis (RA). Analyses of mRNA expression
levels of genes involved in extracellular matrix remodeling formation in colony-stimulating factor-1 (CSF-1)- or IL-34-differentiated macrophages
(Mφ) derived from monocytes of synovial fluid in RA (n = 3). Data are shown as relative quantity (RQ) in CSF-1 Mφ, as described in “Methods”. *P < 0.05
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aFig. 5 Anti-colony stimulating factor-1 receptor (anti-CSFR1) antibody reduces the production of inflammatory mediators in synovial tissue in
rheumatoid arthritis (RA). a IL-6 ELISA production in supernatants of RA synovial tissue after 24-h incubation in medium alone or increasing
concentrations of colony stimulating factor-1 (CSF-1) or IL-34 (n = 7). b-d IL-6 ELISA production in supernatants of RA synovial tissue after 4 days
of incubation in medium alone in the presence of IgG1 or anti-IL-34 antibody (Ab) (5 μg/ml for both, n = 5) (b), anti-CSF-1 Ab (5 μg/ml, n = 3) (c),
or increasing concentrations of IgG4 or huAB1 (n = 5) (d). e, f Multiplex analysis of protein production in supernatants of RA synovial tissue after 4
days of incubation in medium alone in the presence of 1 μg/ml IgG4 or 1 μg/ml huAB1 (n = 4). Boxes represent the 25th–75th percentiles, lines
within the boxes mark the median value, and lines outside the boxes denote the 10th and 90th percentiles. *P < 0.05 and **P < 0.01
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and we observed a trend towards a reduction in produc-
tion of TNF, IL-1β, ENA-78 and MMP-2, although the dif-
ferences were not significant (Fig. 5f). In contrast, we did
not observe differences in the production of SDF-1, TAC,
NAP-2, and MMP-7 (data not shown). Together, these re-
sults demonstrate that CSF1R signaling inhibition, but not
individual inhibition of the two receptor ligands, is able to
reduce the production of inflammatory mediators in syn-
ovial tissue in RA.
CSF1R blockade is protective in CIA
Given the efficacy of CSF1R blockade in RA synovial tis-
sue, we examined the effect of the blocking anti-mouse
CSF1R antibody muAB5 in vivo using the murine CIA
model of arthritis. Prophylactic administration of
muAB5 (30 mg/kg) significantly reduced the severity of
the arthritis compared with the vehicle control (Fig. 6a).
Histological analyses of the hind paws of the mice con-
firmed the protective effect of muAB5, as the scores for
inflammation, cartilage damage, pannus formation, and
bone erosion were all improved in muAB5-treated mice
(Fig. 6b). Semiquantitative analysis demonstrated that
muAB5 administration drastically and significantly re-
duced all these analyzed parameters (Fig. 6c). As CSF1R
signaling also supports osteoclastogenesis, we quantified
the serum levels of the bone resorption marker,
TRAP5b. Anti-CSF1R-treated mice had a significant re-
duction in TRAP5b compared with vehicle-treated mice
(Fig. 6d). Interestingly, administration of muAB5 was
more effective than Enbrel (10 mg/kg) in reducing the
severity of arthritis and in improvement of all histological,
radiological, and serological parameters (Fig. 6a-d). Anti-
CSF1R treatment was associated with reduced macro-
phage infiltration in the synovial tissue (Fig. 6e). The front
paws and knees of the mice were examined by immuno-
histochemical analysis for the presence of macrophages by
F4/80 staining. Macrophage numbers were significantly
reduced in muAB5-treated mice compared to vehicle
control. Enbrel had no significant effect on tissue macro-
phage numbers.
We next examined the therapeutic effect of muAB5
treatment in the CIA model. muAB5 administered after
the induction of arthritis significantly inhibited pannus
formation and bone destruction (Fig. 7a). Anti-CSF1R
treatment did not have a significant effect on histological
parameters of inflammation or cartilage destruction. In
this study Enbrel also had no significant effect on in-
flammation or cartilage destruction. Therapeutic treat-
ment with muAB5 also reduced serum TRAP5b and the
number of tissue macrophages (Fig.7b and 7c). The lack
of an effect of muAB5 on inflammation, despite reducing
tissue macrophage numbers, is possibly due to the fact
that late-stage inflammation in the mouse CIA model
is driven in part by high infiltration of neutrophils.
This is in contrast to human RA in which macro-
phages predominate.
Discussion
In the present study we demonstrated that specific anti-
bodies against CSF1R, which prevent binding of both
CSF-1 and IL-34 to their receptor, reduce the severity of
CIA and the production of inflammatory mediators in
RA synovial tissue explants ex vivo. Conversely,
neutralization of CSF-1 or IL-34 individually had no de-
tectable effect on inflammatory gene expression in RA
synovial tissue. This latter observation was surprising, as
CSF-1 deficiency or neutralization in animal models of
RA has clear therapeutic effects [11, 12]. Our data might
suggest that in CIA, CSF-1 plays an important role in
promoting the differentiation and survival of mature
monocytes in the periphery before or as they are enter-
ing the inflamed tissue, as observed in certain murine
models of lung and peritoneal inflammation [6], while in
RA synovial explants, synovial macrophages are no lon-
ger dependent upon CSF-1 alone. Instead, synovial mac-
rophages may also utilize IL-34 as a survival factor. In
line with this, CSF-1 and IL-34 are detected at equiva-
lent concentrations in synovial fluid from patients with
RA, and here we confirm and extend previous observa-
tions that both CSF-1 and IL-34 are produced locally in
RA synovial tissue [35, 36]. However, stimulation of RA
synovial biopsies with either CSF-1 or IL-34 failed to in-
fluence acute expression of inflammatory mediators,
possibly indicating that endogenous synovial production
of CSF-1 and/or IL-34 in RA is saturating in regard to
CSF1R availability.
Our inability to modulate RA synovial explant gene
expression by neutralizing CSF-1 and IL-34 individually
further supports the notion that these two cytokines
are largely redundant in supporting the differentiation
and survival of most tissue macrophage populations.
Some subtle differences have been noted between CSF-
1 and IL-34 in the strength and kinetics with which
they activate CSFR1 [30–32]. Indeed, global gene ex-
pression analysis of human monocytes differentiated
with IL-34 and M-CSF revealed that of the genes regu-
lated by these cytokines, quantitative differences in the
induction were noted for approximately 30 % of the
genes [45]. Consistent with this, of 336 genes involved
in processes contributing to pathological changes in
RA, such as angiogenesis, inflammation, and tissue re-
modeling, we observed only 18 genes that were differ-
entially expressed by CSF-1 and IL-34 Mφ. However, as
we observe that CSF-1 (detected in cells surrounding
the blood vessels) and IL-34 (throughout the synovial
sublining and intimal lining layers) are expressed in dif-
ferent regions of the synovium, these cytokines could
potentially contribute to the phenotypic heterogeneity
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of macrophages observed in the sublining and intimal
lining layers of synovium in inflammatory arthritis [46].
Our results provide the first direct evidence that targeting
of CSF1R has anti-inflammatory effects in not only animal,
but also human models of established RA. Previous studies
have observed protective effects against pathological
changes in animal models of RA using pharmacological in-
hibitors of CSF1R kinase activity [22, 23]. However, con-
cerns have been raised that these compounds can also
target other tyrosine kinases relevant to pathological change
Fig. 6 Prophylactic treatment with anti-colony stimulating factor-1 receptor (anti-CSF1R) prevents pathological progression in collagen-induced
arthritis (CIA). a Daily global arthritic scores for mice treated intraperitoneally every 3 days with vehicle, Enbrel, or muAb5. Treatment continued
three times weekly from day 0 with control vehicle (triangles), Enbrel (10 mg/kg) (circles) or muAb5 (30 mg/kg) (squares). b Representative images
of pathological appearances of the joints in the indicated treatment group, visualized by H&E staining. Note the representative areas of synovial
cellular infiltration and pannus formation (arrows). c Inflammation (I), pannus formation (PF), cartilage damage (CD), and bone damage (BD) scores
for mice in each treatment group. Data are mean ± standard error of the mean (SEM) for each group (n = 12 animals per group). #P < 0.05 vs
vehicle and **P < 0.01. d, e Band 5 tartrate-resistant acid phosphatase isoform b (TRAP5b) plasma levels (d) and number of F4/80-positive cells in
five × 200 fields (e) in the inflamed joints of mice in each treatment group. Symbols represent values obtained from individual animals, bars represent
the mean, and error bars indicate the SEM. #P < 0.05 vs naive and ###P < 0.001 vs naïve. ***P < 0.001
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in RA [17]. While this manuscript was in preparation, Toh
and colleagues reported that another CSF1R-specific Ab
could prophylactically prevent inflammation and joint dam-
age in CIA [47]. Intriguingly, the same antibody did not
suppress inflammation in the murine serum transfer model
of arthritis, while retaining its capacity to block cartilage
and bone destruction. The authors attributed this discrep-
ancy to potentially differential roles for macrophage recruit-
ment and activation in these animal models [47].
Similarly, conflicting results using different CSF1R-
blocking antibodies in other animal disease models have
led to questions about the feasibility of this strategy [17].
For instance, the anti-CSFR1 Ab AFS98, which rapidly re-
duces monocytes and tissue macrophages in vivo, confers
protection in murine models of lung and peritoneal inflam-
mation [6]. However, another Ab M279, which reduces the
F4/80hiLy6lo monocyte population and tissue macrophages
more slowly, does not display anti-inflammatory effects in
similar models, but exacerbates graft-versus-host disease
[18]. The difference in activity of AFS98 and M279 could
be due to differences in Fc effector function [17]. AFS98 is
a rat IgG2a with greater potential for Fc effector function
compared to M279, which is a rat IgG1. muAb5 is a mouse
IgG1 and expected to have low Fc effector function, similar
to M279. In our study, muAb5 reduced the same circulat-
ing monocyte population observed with M279, but pro-
vided almost complete protection against all parameters of
disease in CIA.
These studies have led to the suggestion that in some
inflammatory diseases, anti-CSF1R therapy might aggra-
vate pathological changes by depleting the tissue of the
tolerizing resident tissue macrophages and allowing their
replacement by pro-inflammatory monocyte popula-
tions, or by promoting pro-inflammatory re-polarization
of tissue macrophages [17]. These concerns can only be
addressed empirically in the clinic, but it is noteworthy
that huAB1 treatment reduced the production of pro-
inflammatory cytokines (IL-6, TNF, and IL-1β), chemo-
kines (CXCL-8, GCP-2, MIG, IP-10, CCL-2, and CCL7),
and MMPs (MMP-2 and MMP-9) in RA synovial tissue.
This suggests that CSF1R blockade in the inflamed tissue
does not result in conversion of synovial macrophages to a
more pro-inflammatory functional phenotype, consistent
with recent observations that environmental stimuli present
in synovial tissue, such as IgG complexes and angiopoietins,
can override polarization conditions to regulate macro-
phage gene expression [48, 49]. Experimentation in synovial
biopsies cannot address the possibility that circulating pro-
inflammatory monocytes might replace synovial macro-
phages following anti-CSF1R treatment, but studies of
monocyte migration using scintigraphy in RA patients has
indicated that macrophage turnover in synovial tissue is
slow, and even during successful therapy, the rate of mono-
cyte immigration into synovial tissue is unchanged [50, 51],
raising the possibility that CSF-1 maintains distinct mono-
cyte populations in mouse and man.
Fig. 7 Therapeutic treatment with anti-colony stimulating factor-1 receptor (anti-CSF1R) suppresses bone destruction and pannus formation in
collagen-induced arthritis (CIA). a Histopathological assessment of CIA in mice treated with vehicle, Enbrel, or muAB5 after the initiation of arthritis.
*P < 0.05 and **P < 0.01 vs vehicle. I inflammation, PF pannus formation, CD cartilage damage, BD bone damage. b, c Band 5 tartrate-resistant acid
phosphatase isoform b (TRAP5b) plasma levels (b) and number of F4/80-positive cells in five × 200 fields (c) in the inflamed joints of mice in each
treatment group. Symbols represent values obtained from individual animals, bars represent the mean, and error bars indicate the standard error of the
mean. **P < 0.01 vs vehicle and ###P < 0.001 vs naïve. ***P < 0.001
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Conclusions
Simultaneous interference with CSF-1 and IL-34 signal-
ing to CSF1R suppresses pro-inflammatory gene expres-
sion in RA synovial tissue, and decreases pathology in
both prophylactic and therapeutic treatment strategies
in CIA, further validating CSF1R as a potential thera-
peutic target in RA.
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